{"id":"ak112-nab-paclitaxel-gemcitabine","safety":{"commonSideEffects":[{"rate":"46%","effect":"Neutropenia"},{"rate":"34%","effect":"Anemia"},{"rate":"21%","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL4303645","moleculeType":"Small molecule","molecularWeight":"389.89"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Nab-paclitaxel is a microtubule inhibitor that works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells.","oneSentence":"Inhibits microtubule dynamics by binding to tubulin, thereby inhibiting cell division","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:51:43.695Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06646055","phase":"PHASE1, PHASE2","title":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2025-01-21","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":110},{"nctId":"NCT06944106","phase":"PHASE2","title":"A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-03-28","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT06491472","phase":"PHASE2","title":"Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-07-15","conditions":"Pancreatic Cancer","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AK112, nab-paclitaxel, gemcitabine","genericName":"AK112, nab-paclitaxel, gemcitabine","companyName":"Akeso","companyId":"akeso","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits microtubule dynamics by binding to tubulin, thereby inhibiting cell division Used for Breast cancer, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}